Suppr超能文献

米索前列醇:一种有效的宫颈成熟和引产药物。

Misoprostol: an effective agent for cervical ripening and labor induction.

作者信息

Wing D A, Rahall A, Jones M M, Goodwin T M, Paul R H

机构信息

Department of Obstetrics and Gynecology, Los Angeles County-University of Southern California Medical Center 90033, USA.

出版信息

Am J Obstet Gynecol. 1995 Jun;172(6):1811-6. doi: 10.1016/0002-9378(95)91416-1.

Abstract

OBJECTIVE

Our purpose was to compare the safety and efficacy of intravaginal misoprostol versus intracervical prostaglandin E2 gel (dinoprostone) for preinduction cervical ripening and induction of labor.

STUDY DESIGN

Two hundred seventy-six patients with indications for induction of labor and unfavorable cervices were randomly assigned to receive either intravaginal misoprostol or intracervical dinoprostone. Twenty-five micrograms of misoprostol were placed in the posterior vaginal fornix every 3 hours, with a potential maximum of eight doses. Prostaglandin E2 in gel form, 0.5 mg, was placed in the endocervix every 6 hours, with a maximum of three doses. Further medication was withheld with the occurrence of spontaneous rupture of membranes, entry into active phase of labor, or a "prolonged contraction response."

RESULTS

Among those evaluated, 138 received misoprostol and 137 received dinoprostone. The average interval from start of induction to vaginal delivery was shorter in the misoprostol group (1323.0 +/- 844.4 minutes) than in the dinoprostone group (1532.4 +/- 706.5 minutes) (p < 0.05). Need for oxytocin augmentation of labor occurred more commonly in the dinoprostone group (72.6%) than in the misoprostol group (45.7%) (p < 0.0001). There were no significant differences in the routes of delivery. Twenty-eight of the misoprostol-treated patients (20.3%) and thirty-eight of the dinoprostone-treated patients (27.7%) required abdominal delivery. Complications such as uterine tachysystole and thick meconium passage occurred with similar frequency in the two treatment groups.

CONCLUSIONS

Intravaginal administration of misoprostol appears to be as effective as intracervical dinoprostone for cervical ripening and labor induction. Complications associated with prostaglandin administration were not statistically different between the two treatment groups. The cost of misoprostol ($0.36/100 micrograms) is much less than that of dinoprostone ($75/0.5 mg).

摘要

目的

我们的目的是比较阴道内使用米索前列醇与宫颈内使用前列腺素E2凝胶(地诺前列酮)用于引产术前宫颈成熟和引产的安全性及有效性。

研究设计

276例有引产指征且宫颈条件不佳的患者被随机分配接受阴道内米索前列醇或宫颈内地诺前列酮治疗。每3小时在阴道后穹窿放置25微克米索前列醇,最大剂量为8剂。每6小时在宫颈内放置0.5毫克凝胶型前列腺素E2,最大剂量为3剂。一旦出现胎膜自然破裂、进入产程活跃期或“宫缩延长反应”,则停止进一步用药。

结果

在接受评估的患者中,138例接受了米索前列醇治疗,137例接受了地诺前列酮治疗。米索前列醇组从引产开始至阴道分娩的平均间隔时间(1323.0±844.4分钟)短于地诺前列酮组(1532.4±706.5分钟)(p<0.05)。地诺前列酮组(72.6%)比米索前列醇组(45.7%)更常需要使用缩宫素加强宫缩(p<0.0001)。分娩方式上无显著差异。米索前列醇治疗组中有28例患者(20.3%)和地诺前列酮治疗组中有38例患者(27.7%)需要剖宫产。子宫收缩过速和胎粪排出浓稠等并发症在两个治疗组中的发生率相似。

结论

阴道内使用米索前列醇在宫颈成熟和引产方面似乎与宫颈内使用地诺前列酮一样有效。两个治疗组中与前列腺素给药相关的并发症在统计学上无差异。米索前列醇的成本(0.36美元/100微克)远低于地诺前列酮(75美元/0.5毫克)。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验